First-Line Treatment Selection for Advanced Clear Cell RCC Based on Risk Scores

Intermediate- and Poor-Risk Disease

The European Society for Medical Oncology recommends nivolumab/cabozantinib as a preferred first-line treatment, demonstrating superior PFS (16.6 vs 8.4 months) and OS (49.5 vs 35.5 months) compared to sunitinib, with benefits maintained across all IMDC risk groups 1, 2
The National Comprehensive Cancer Network recommends nivolumab/ipilimumab as a Category 1 preferred option with demonstrated OS benefit (HR 0.70) and should be strongly considered as first-line therapy 3, 4, 5
Cabozantinib monotherapy is a Category 2A preferred option for intermediate/poor-risk patients, showing significantly increased PFS and higher ORR versus sunitinib in the CABOSUN trial 3, 4, 5

The European Society for Medical Oncology recommends ICI combinations (nivolumab/cabozantinib, pembrolizumab/axitinib, pembrolizumab/lenvatinib) as options with Level 1b evidence across all risk groups 1, 2
Single-agent VEGFR TKIs, such as sunitinib, may be preferred due to lack of clear OS superiority for ICI combinations in this subgroup, with sunitinib demonstrating superior PFS and OS trend versus interferon-alpha 1, 6, 7, 8

When selecting between ICI combinations, no single PD-1 inhibitor/VEGFR TKI combination is preferred over others; indirect cross-trial comparisons are not recommended 1
Axitinib/avelumab is NOT recommended as it failed to demonstrate OS benefit compared to sunitinib despite PFS improvement, earning an ESMO-MCBS score of only 3 1

Pazopanib requires monitoring of liver function before and during treatment due to 30% grade 3 ALT elevation and 21% AST elevation rates 6, 7
ICI combinations require monitoring for immune-mediated adverse events, with 35% of patients requiring high-dose steroids and 22% experiencing treatment-related discontinuation with ipilimumab/nivolumab 3, 4